Core Viewpoint - The 91st National Pharmaceutical Trade Fair in Nanjing showcased the strength of Hainan's pharmaceutical industry, with 12 local companies participating under the theme "Hainan's Good Medicines" [1][2] Group 1: Event Overview - The trade fair is a significant professional event in China's pharmaceutical and health sector, featuring over 2,000 outstanding companies [1] - Hainan's exhibition area covered nearly 300 square meters, highlighting the participation of notable local pharmaceutical companies [1] Group 2: Participating Companies and Products - The participating companies included Hainan Huanglong Pharmaceutical, Haikou Pharmaceutical Factory, Hainan Bikai Pharmaceutical, among others, showcasing over 200 product varieties [1] - The exhibited products addressed various treatment areas, including cardiovascular, anti-tumor, gynecology, pediatrics, and immune regulation [1] Group 3: Market Impact - The event served as an efficient platform for companies to expand their market presence, enhance brand image, and seek collaborations [2] - Hainan's participation aimed to improve the overall brand image and market competitiveness of its pharmaceutical industry [2]

Core Viewpoint - The 37th Academic Exchange Conference on Spleen and Stomach Diseases organized by the Chinese Association of Traditional Chinese Medicine was successfully held, showcasing the latest clinical research and developments in the treatment of gastrointestinal diseases, particularly highlighting the unique product "Fengliao Stomach and Intestine Kang Granules" from Hainan Haiyao Co., Ltd [1][2]. Group 1: Company Developments - Hainan Haiyao presented its unique traditional Chinese medicine product, Fengliao Stomach and Intestine Kang Granules, at the conference, which has shown promising results in clinical evaluations [1][2]. - The clinical study of Fengliao Stomach and Intestine Kang Granules demonstrated its effectiveness in treating adult acute diarrhea, showing a trend of better efficacy compared to the control group [2]. - The product has received multiple registrations and certifications, including five registration approvals and two invention patents, and has been recognized in twelve treatment guidelines [2]. Group 2: Market Trends - The sales of digestive system medications in China's urban retail pharmacies have shown steady growth, with a rebound in the first quarter of 2025 reaching nearly 15 billion yuan, a year-on-year increase of 2.29% [3]. - The market for traditional Chinese medicine in digestive diseases has remained stable, with significant growth in specific categories, such as stomach medications, which accounted for 24.09% of the market share [3]. - The increasing willingness of consumers to use natural and low-side-effect traditional Chinese medicine products is expected to enhance the market prospects for Hainan Haiyao's flagship products [3]. Group 3: Research and Development - Hainan Haiyao has established a robust R&D system, focusing on innovative drugs, formulations, and traditional Chinese medicine, with significant investments in major disease areas [5][6]. - The company has invested 397 million yuan in R&D over the past three years, with 124 million yuan allocated in 2024, representing 12.48% of its revenue [5]. - Two key innovative drugs, Fluorofenone and Painegabin, are currently in Phase II clinical trials, indicating the company's commitment to advancing its drug development pipeline [6].